Press release
Hemophilia B Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Hemophilia B Pipeline. Dive into DelveInsight's comprehensive report today! @ Hemophilia B Pipeline Outlook [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hemophilia B Pipeline Report
* On 03 September 2025, Pfizer announced a long-term safety and efficacy follow-up for individuals with Hemophilia B who were previously enrolled in the C0371005 (formerly SPK-9001-101) trial. In addition, the company is initiating a dose-escalation sub-study designed to evaluate the safety, tolerability, and kinetics of a higher dose, along with long-term safety and efficacy monitoring. Notably, participants in this sub-study are not required to have taken part in the original C0371005 trial.
* DelveInsight's Hemophilia B Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hemophilia B treatment.
* The leading Hemophilia B Companies such as Shanghai Vitalgen BioPharma, Belief BioMed, TiumBio, Jiangsu Gensciences, Centessa Pharmaceuticals, Takeda, Sanofi, GC Biopharma Corp, Equilibra Bioscience LLC, Regeneron Pharmaceuticals, ISU Abxis and others.
* Promising Hemophilia B Therapies such as REGV131, LNP1265, APVO101, SPK-9001, ANB-002, Benefix, IB1001, marstacimab and others.
Get insights into Hemophilia B Clinical Trials, emerging therapies, and leading companies with DelveInsight @ Hemophilia B Treatment Drugs [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hemophilia B Emerging Drugs Profile
* BBM-H901: Belief Biomed
BBM-H901 is indicated for prophylactic treatment of bleeding in adults with hemophilia B. BBM-H901 is designed to restore the production of factor IX (FIX) the blood-clotting protein that is faulty or missing in people with hemophilia B by delivering a functional copy of the F9 gene to liver cells, which are the main producers of clotting factors in the body. Gene therapy components are delivered to liver cells by a modified, harmless adeno-associated virus (AAV) that works as a vehicle. The gene therapy is given as a single intravenous (into-the-vein) infusion. The drug BBM-H901 is in the Phase III clinical trial for the treatment of hemophilia B.
* ISU304: ISU ABXIS
ISU304 (Dalcinonacog alfa, DalcA) is a modified recombinant Factor IX protein for the prophylactic therapy of patients with Hemophilia B which is caused by a deficiency of coagulation FIX. It is designed to be administered subcutaneously and achieves normal FIX activity levels to prevent bleeding of patients with hemophilia B. Currently approved protein replacement therapy for hemophilia B rely on intravenous injection. With a subcutaneous injection, ISU304 is expected to improve the quality of life and treatment convenience in patients with hemophilia B. The drug is in phase II stage of its clinical trial for the treatment of hemophilia B.
* TU7710: TiumBio
TU7710 is a bypassing agent treatment for patients with neutralizing antibodies and is an innovative drug candidate with a half-life 6~7 times greater than conventional treatments through our transferrin fusion gene recombination technology. TU7710 is expected to dramatically improve the convenience and quality of life of hemophilia patients with neutralizing antibodies. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Hemophilia B.
The Hemophilia B Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia B with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia B Treatment.
* Hemophilia B Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hemophilia B Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia B market
Explore groundbreaking therapies and clinical trials in the Hemophilia B Pipeline. Access DelveInsight's detailed report now! @ New Hemophilia B Drugs [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hemophilia B Companies
Shanghai Vitalgen BioPharma, Belief BioMed, TiumBio, Jiangsu Gensciences, Centessa Pharmaceuticals, Takeda, Sanofi, GC Biopharma Corp, Equilibra Bioscience LLC, Regeneron Pharmaceuticals, ISU Abxis and others.
Hemophilia B pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Hemophilia B Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Learn about new Hemophilia B drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hemophilia B Market Drivers and Barriers [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hemophilia B Pipeline Report
* Coverage- Global
* Hemophilia B Companies- Shanghai Vitalgen BioPharma, Belief BioMed, TiumBio, Jiangsu Gensciences, Centessa Pharmaceuticals, Takeda, Sanofi, GC Biopharma Corp, Equilibra Bioscience LLC, Regeneron Pharmaceuticals, ISU Abxis and others.
* Hemophilia B Therapies- REGV131, LNP1265, APVO101, SPK-9001, ANB-002, Benefix, IB1001, marstacimab and others.
* Hemophilia B Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hemophilia B Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight's in-depth Hemophilia B Pipeline report today! @ Hemophilia B Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Hemophilia B: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hemophilia B - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* BBM-H901: Belief Biomed
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ISU304: ISU ABXIS
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* TU7710: TiumBio
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Hemophilia B Key Companies
* Hemophilia B Key Products
* Hemophilia B - Unmet Needs
* Hemophilia B - Market Drivers and Barriers
* Hemophilia B - Future Perspectives and Conclusion
* Hemophilia B Analyst Views
* Hemophilia B Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hemophilia-b-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemophilia B Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4170778 • Views: …
More Releases from ABNewswire
A Gem of Joy ABA Breaks Barriers to Access with In-Home Therapy Services for Fam …
A Gem of Joy ABA offers in-home therapy services for Maryland families, breaking barriers to access and providing personalized support for children's development.
Maryland - A Gem of Joy ABA, a leading provider of autism therapy solutions, is making a transformative impact on families across Maryland by offering flexible and personalized in-home ABA Therapy. This innovative approach aims to break down barriers to care by delivering services directly to families' homes,…
Ontario Therapy Takes Action to Break Mental Health Stigma with DBT Therapy in B …
Ontario Therapy is expanding access to DBT therapy in Bradford, helping individuals overcome mental health challenges with effective, stigma-free support and coping strategies.
Bradford, ON - Ontario Therapy is taking significant steps to combat the stigma surrounding mental health by expanding access to Dialectical Behavior Therapy (DBT) in Bradford. With a mission to create more inclusive and supportive mental health care environments, Ontario Therapy is offering DBT therapy to help individuals…
Kelemer Brothers Helps Rockville Homeowners Save on Energy Bills with High-Effic …
Kelemer Brothers helps Rockville homeowners reduce energy bills with high-efficiency window replacements, improving insulation and home comfort.
Rockville, MD - Kelemer Brothers, a leading provider of window replacement services in Rockville, MD, is helping homeowners reduce their energy bills by offering high-efficiency Window replacement Rockville MD [https://www.kelemerbrothers.com/window-replacement-rockville-md/]. With the growing demand for energy-saving solutions, Kelemer Brothers is proud to provide cutting-edge window technology designed to enhance energy efficiency and comfort in…
Attorney Big Al's Proven Strategies Help Richmond, VA Residents Successfully Nav …
Attorney Big Al's proven strategies help Richmond, VA residents navigate personal injury claims with confidence, ensuring successful outcomes and fair compensation.
Richmond, VA - Attorney Big Al, a trusted name in personal injury law, continues to provide Richmond residents with effective legal representation designed to help clients recover compensation and peace of mind after accidents. With a record of proven strategies and years of experience, Attorney Big Al and his team…
More Releases for Hemophilia
Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth: Stren …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
What Is the Expected CAGR for the Hemophilia Market Through 2025?
In recent times, there has been a significant expansion in the hemophilia market. The market, which stood at $13.83 billion in 2024, is projected to inflate to $15.13 billion in 2025, exhibiting a compound annual growth rate (CAGR)…
Global Hemophilia Market Size & Trends
According to a new market research report published by Global Market Estimates, the global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028.
During the forecast period, the global hemophilia market is anticipated to experience growth due to advancements in medical research, an increase in hemophilia incidence, and rising awareness and diagnosis.
Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and…
Acquired Hemophilia Treatment Market - Embracing Hope, Defying Hemophilia: Trans …
Newark, New Castle, USA: The "Acquired Hemophilia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Acquired Hemophilia Treatment Market: https://www.growthplusreports.com/report/acquired-hemophilia-treatment-market/7748
This latest report researches the industry structure,…
Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand…
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports.
Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged…
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504
The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes…
